Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9616 posts found.

ea_pharma

Eisai announces agreement to set up new gastrointestinal speciality company

March 30, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Ajinomoto, Eisai, absorption, acquisition, ea pharma, gastrointestinal, merger, speciality

Eisai (TYO: 4523) and Ajinomoto Co. (TYO: 2802) have announced an agreement to establish a new gastrointestinal speciality pharmaceutical company, …
News
acadia

FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug

March 30, 2016 Research and Development, Sales and Marketing FDA, Parkinson's, Parkinsons, acadia, nuplazid, pimavanserin, psychosis

Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) …
News
biosimilars_squiggly_thing

Biosimilars could save healthcare systems $100bn by 2020

March 30, 2016 Research and Development, Sales and Marketing biosimilars

The growth of the market for biosimilar drugs has the potential to save EU and US healthcare systems up to …
News
gsk_corp_hq_brentford_2

GSK’s Nucala gets regulatory approval in Japan to treat bronchial asthma

March 29, 2016 Manufacturing and Production, Research and Development GlaxoSmithKline, Japan, Nucala, US FDA, bronchial asthma

GlaxoSmithKline (LSE: GSK) on Tuesday said the Japanese regulators have approved its drug to treat bronchial asthma.  The Japanese Ministry …
News
valeant

Valeant’s outgoing CEO subpoenaed by US congressional committee

March 29, 2016 Medical Communications, Research and Development Drug pricing, Michael Pearson, US, Valeant, committee, pearson, pharma, price hikes, senate aging committee, subpoena, subpoenaed

The US Senate Aging Committee has announced the issuing of a subpoena to the outgoing CEO of Valeant Pharmaceuticals, Michael …
News

TREND: Rare disease, cancer drugs will drive pharma M&A’s, growth

March 29, 2016 Manufacturing and Production, Research and Development, Sales and Marketing M&A, MA, Orphan Drugs, cancer drugs

Moody’s Investor Service lowered its growth outlook for the global pharma sector but maintained the mergers and acquisitions in the …
Feature
novo_flag

Novo Nordisk breaks ground on new $2 billion production facility in North Carolina

March 29, 2016 Manufacturing and Production, Research and Development $2 billion, Clayton, Novo, Novo Nordisk, building, diabetes, nordisk, north carolina, production facility

Novo Nordisk has begun work on a new $2 billion production facility in Clayton, North Carolina, which will produce active …
News
shutterstock_92671375

US FDA issues observations for Natco Pharma’s Indian plants

March 29, 2016 Manufacturing and Production, Research and Development, Sales and Marketing

Shares in India-based Natco Pharma (BOM: 524816) dropped on the Bombay Stock Exchange following news the US Food and Drug …
News

Portola Pharma stock drops on dismal Phase III trial results for blood-clot drug

March 29, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Portola Pharmaceuticals, blood clot drug, drug trial, phase III

Shares in Portola Pharmaceuticals (Nasdaq: PTLA) dropped after the company reported disappointing late-stage trial results for its blood clotting drug. …
News
brintellix

FDA issues CRL for Takeda/Lundbeck’s Brintellix

March 29, 2016 Manufacturing and Production, Research and Development Lundbeck, Takeda, brintellix

Takeda and Lundbeck have received a complete response letter from the US Food and Drug Administration (FDA) for the supplemental …
News
logo

Phase III trial initiated for enzalutamide in treatment of prostate cancer

March 24, 2016 Research and Development Astellas, Medivation, arches, clinical trial, enzalutamide, phase 3, phase III, prostate cancer

Astellas Pharma (TSE: 4503) and Medivation (NASDAQ:MDVN) have announced the initiation of the ARCHES Phase III clinical trial to evaluate …
News
msd

MSD teams up with Harvard to develop new leukaemia treatments

March 24, 2016 Medical Communications, Research and Development AML, Harvard, MSD, leukaemia

MSD has entered a new collaboration with Harvard University aimed at developing innovative new small-molecule therapeutics for leukaemia and other …
News

EMA to review Pfizer’s Xeljanz for patients with rheumatoid arthritis

March 24, 2016 Research and Development, Sales and Marketing EMA, Pfizer, Xeljanz, approval, authorisation, marketing, review, rheumatoid arthritis

Pfizer (NYSE: PFE) has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) …
News
teva_copy

Teva announces FDA approval for asthma injection, Cinqair

March 24, 2016 Research and Development, Sales and Marketing FDA, Teva, approval, asthma, cinqair

The US Food and Drug Administration has approved Cinqair (reslizumab), an injection for patients with severe asthma developed by Teva …
News

Biotech Micreos appoints CMO to lead clinical development of antibiotic alternative

March 23, 2016 Research and Development

Dr Johan Frieling has been appointed as the new chief medical officer of Dutch biotech company Micreos, at a pivotal …
Appointment
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026